Regional Citrate Anticoagulation Versus No Anticoagulation During Continuous Renal Replacement Therapy in Critically Ill Patients at High Risk of Bleeding: A Meta-analysis of Randomized Controlled Trials.
Wenlong Li, Jun Xie, Chong Huang et al.
✦ AI-curated · Sources linked
In 30 seconds
This meta-analysis evaluated regional citrate anticoagulation (RCA) versus no anticoagulation (NA) during continuous renal replacement therapy (CRRT) in critically ill patients at high bleeding risk. Seventeen randomized controlled trials with 893 patients were analyzed. RCA significantly prolonged filter lifespan by 13.82 hours and reduced major bleeding risk (RR: 0.37; 95% CI 0.16-0.87), although it increased risks of citrate accumulation and hypocalcemia.
Key findings
- RCA prolonged filter lifespan by 13.82 hours (95% CI 10.83-16.81) compared to NA.
- RCA reduced the incidence of circuit clotting (RR: 0.20; 95% CI 0.12-0.35).
- RCA was associated with a higher risk of citrate accumulation (RR: 4.67; 95% CI 1.30-16.77).
- RCA significantly reduced major bleeding (RR: 0.37; 95% CI 0.16-0.87).
Why it matters
The findings suggest that RCA may enhance circuit longevity and reduce major bleeding in critically ill patients undergoing CRRT, which is crucial for patient management in high-risk settings. However, clinicians should be aware of the potential for metabolic complications.
What to keep in mind
The certainty of evidence for the reduction in major bleeding was low, warranting cautious interpretation of the findings.